NCT07152444View on ClinicalTrials.gov

A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2026

Conditions
Uncontrolled Hypertension
Interventions
DRUG

QLS1410 (CYP11B2 inhibitor)

QLS1410 tablets

DRUG

placebo

Matching placebo tablets

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY